KB-1371

SAR156597-IL4-hIgG4-S228P

45582

Home » Antibodies » SAR156597-IL4-hIgG4-S228P

Background of SAR156597-IL4-hIgG4-S228P

Romilkimab (SAR156597) represents an engineered humanized IgG4 antibody designed to bind and neutralize IL-4 and IL-13. This innovative therapeutic agent has demonstrated efficacy in reducing thymus and activation-regulated chemokine (TARC), also known as chemokine (C-C motif) ligand 17, in patients diagnosed with idiopathic pulmonary fibrosis (IPF). TARC serves as a direct downstream target induced by IL-4 and IL-13 receptor activation and stands as a pivotal serum marker utilized to evaluate target engagement in the treatment of IPF.

Specifications

Catalog Number	KB-1371
Antibody Name	SAR156597-IL4-hIgG4-S228P
Isotype	Human IgG4-S228P, kappa
Target	IL4
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Huang X-L , Wang Y-J , Yan J-W , et al . Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res 2015;64:151–9.
Allanore Y , Denton C , Khanna D , et al . Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): a randomized, double-blind, placebo-controlled, 24-week, proof of concept study. Arthritis Rheumatol 2019;71(abstract 1653).